Cipla Gets New Price-Violation Notice From India Regulator
This article was originally published in PharmAsia News
India's drug-pricing regulator served notice on Cipla for violating the rules in pricing its generic version of the antibiotic ciprofloxacin within the past nine months. At the same time, the Indian Supreme Court is considering another accusation that Cipla overcharged for a range of antibiotics and anti-asthma drugs four years ago. Cipla contends the new notice issued by the National Pharmaceutical Pricing Authority is covered by the pending court case brought by Cipla. Cipla contended in that case that NPPA's penalties were untenable and could not be sustained. (Click here for more
You may also be interested in...
A new report focused on the European market says that winning trust is the key to taking AI adoption to the next stage. That approach was praised by MedTech Europe CEO Serge Bernasconi.
As the transition period following the UK’s withdrawal from the European Union draws to a close, cosmetics industry stakeholders are following final trade negotiations while readying themselves for new regulatory complexities.
Purdue’s opioid settlement is making headlines for the size of the financial penalty. But the plan to re-imagine Purdue as a ‘public benefit company’ could have far-reaching significance for the industry – if it ever gets off the ground.